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Abstract
Peroxisome Proliferator-Activated Receptor delta (PPAR-δ) is a nuclear receptor transcription 
factor that regulates gene expression during development and disease states such as cancer. 
However, the precise role of PPAR-δ during tumorigenesis is not well understood. Recent data 
suggest that PPAR-δ may have context specific oncogenic and tumor suppressive roles depending 
on the tissue, cell-type, or diet-induced physiology in question. For example in the intestine, pro-
obesity diets, like a high fat diet (HFD), are associated with increased colorectal cancer incidence. 
Interestingly, many of the effects of a HFD in the stem and progenitor cell compartment are driven 
by a robust PPAR-δ program and contribute to the early steps of intestinal tumorigenesis. 
Importantly, the PPAR-δ pathway or its downstream mediators may serve as therapeutic 
intervention points or biomarkers in colon cancer that particularly arise in obese patients. 
Although potent PPAR-δ agonists and antagonists exist, their clinical utility may be enhanced by 
uncovering how PPAR-δ mediates tumorigenesis in diverse tissues and cell-types as well as in 
response to diet.
BACKGROUND
Peroxisome Proliferator-Activated Receptor delta (PPAR-δ) belongs to the Peroxisome 
Proliferator-Activated Receptor (PPAR) subfamily of nuclear receptor transcription factors 
that is comprised of three members (alpha, beta/delta and gamma) (1). PPARs are critical 
regulators of metabolism and exhibit tissue and cell-type specific expression patterns and 
functions that can be altered by physiological cues. Although PPAR isoforms have highly 
homologous structures and have overlapping functions, distinct selective ligands have been 
identified to activate each family member exclusively. PPAR-α is the first member of the 
family that was cloned and characterized in mouse liver where it regulates lipid homeostasis 
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and reduces triacylglycerol levels. PPAR-γ has been extensively studied in adipose tissue 
where it controls adipogenesis, lipid metabolism and enhances glucose metabolism (1). In 
particular, PPAR-δ is highly expressed in the intestinal crypts, keratinocytes and oxidative 
skeletal muscle fibers (2) and is a master regulator of lipid metabolism (3). For example, 
PPAR-δ mediated metabolic regulation prevents against diet-induced obesity, metabolic 
syndrome and enhances skeletal muscle endurance and function (4, 5). Furthermore, dietary 
interventions such as fasting (3) and inflammatory cytokines such as tumor necrosis factor 
alpha (TNF-α) and interferon gamma (IFN-γ) (6) augment PPAR-δ signaling. Thus, PPAR-
δ couples diverse dietary, nutritional, or physiological inputs to organismal metabolism (7–
9).
While long chain fatty acids and their derivatives were initially recognized as endogenous 
activators of PPAR-δ pathway, the actual nature of the physiological ligands of PPAR-δ 
remains elusive. In the past decade, in addition to fatty acids, derivatives of arachidonic acid 
(10), lipoperoxidation products (11) and all-trans-retinoic acid (ATRA) (12) have been 
proposed to activate the PPAR-δ pathway. Although a general consensus is lacking, two 
major models have been postulated regarding how nuclear PPAR-δ senses its ligand(s). In 
the first model, it is proposed that the ligands are delivered from the cytoplasm to the 
nucleus by fatty acid binding proteins (FABPs) (13, 14), and in a second model it is 
suggested that the ligands are products of active nuclear lipid metabolism (15). Importantly, 
several very potent and selective small molecule PPAR-δ agonists including GW501516, 
GW0742 (16), and MBX-8025 (17) have been developed and widely used experimentally to 
decipher the biological significance of PPAR-δ mediated transcriptional activity (Figure 1).
PPAR-δ controls transcription both directly and indirectly (1). Direct regulation involves 
partnering with retinoid X receptor (RXR) and binding to peroxisome proliferator response 
elements (PPRE) in the enhancers and promoters of its target genes (Figure 1). Furthermore, 
PPAR-δ mediated transcriptional activation relies on ligand binding and concomitant 
epigenetic mechanisms that include displacement of co-repressors and recruitment of co-
activator associated chromatin-remodeling factors, which orchestrate the framework 
necessary for transcriptional initiation (18). Over the past decade, PPAR-δ or its direct 
transcriptional targets have been demonstrated to bear on diverse cellular functions such as 
stem cell maintenance, cellular differentiation, metabolism and inflammation.
PPAR-δ also regulates a multitude of genes indirectly by affecting the activity of other 
transcription factors through physical interaction or through signal transduction pathways 
that impact the function of other transcription factors (Figure 1). For example, PPAR-δ is 
found to interfere with NFκB pathway (an important pathway in controlling inflammatory 
gene expression) and attenuate inflammation (19). Moreover, PPAR-δ cooperates with β-
catenin (a key transcription factor for cell fate determination) in bone turnover and intestinal 
tumorigenesis (7, 20).
Gene expression analysis studies in combination with chromatin immunoprecipitation 
sequencing (ChIP-seq) have identified direct and indirect PPAR-δ regulated genes (21, 22). 
Well-documented direct targets of PPAR-δ include genes involved in fatty-acid oxidation 
and lipid metabolism such as Cpt1a, Fabp1 and Pdk4, whereas pro-inflammatory cytokines 
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like TNF-α and IL-6 are regulated indirectly. Overall, PPAR-δ controls the expression of a 
large set of genes through different mechanisms that are influenced by the PPAR-δ 
expression levels, interaction with additional transcription factors as well as the abundance 
and nature of its ligands. These different levels of control confer versatility to PPAR-δ 
mediated gene regulation in myriad tissues and cell types during development and disease 
states such as cancer.
PPAR-δ in development and cancer
Several developmental abnormalities have been reported in PPAR-δ-null mice including 
reduced gestational and postnatal body weight as well as abnormalities in multiple tissues 
such as adipose tissue, skin, and intestine (23, 24). In adipose tissue, PPAR-δ deficiency 
leads to a reduction in adipocyte numbers and PPAR-γ expression levels—the PPAR family 
member that controls adipogenesis (23). While PPAR-δ is not directly implicated in the 
regulation of adipogenesis, it contributes to the metabolic response of adipose tissue to 
dietary fatty acids (8, 23). Although PPAR-δ is expendable for homeostatic function in the 
skin, it plays a critical role in skin repair after injuries that disrupt skin integrity. Also it is 
understood that agonist-activated PPAR-δ hampers cellular proliferation and induces 
keratinocyte differentiation (24, 25). Thus, these findings are consistent with the notion that 
PPAR-δ signaling may possess anti-tumorigenic roles in the skin by preventing the growth 
and promoting the differentiation of (pre-)malignant cells through antagonizing the 
expression of proteins known to contribute to keratinocyte hyperproliferation and skin 
tumorigenesis (24–27). However, these anti-tumorigenic effects of PPAR-δ signaling in the 
skin may be context specific as it is observed in only some models of skin cancer (28, 29).
In the intestine, PPAR-δ performs critical regulatory functions and modulates intestinal 
physiology in multiple cell types, yet the underlying mechanisms are poorly understood. For 
instance, PPAR-δ was identified as a crucial factor in Paneth cell differentiation and thus, 
implicating it as a significant player in intestinal homeostasis (30). Paneth cells not only 
possess anti-microbial functions but also constitute a niche component for intestinal stem 
cells (ISCs) that reside at the bottom of the crypt, a location where PPAR-δ expression is the 
highest in the intestine (30, 31). By influencing Paneth cell differentiation, PPAR-δ regulates 
a significant support cell of the ISC, which drives the rapid renewal of the intestinal 
epithelium. In addition, PPAR-δ contributes to intestinal physiology through the control of 
lipid absorption, cholesterol trafficking and enteroendocrine cell function in more 
differentiated or specialized intestinal cell-types (32–34).
Initial reports on the role of PPAR-δ in intestinal tumorigenesis suggested that PPAR-δ is a 
direct transcriptional target of the Wnt/β-catenin pathway, a pathway that governs intestinal 
maintenance and tumorigenesis. Adenomatous polyposis coli (APC) orchestrates the 
destruction of cytoplasmic β-catenin in the absence of an upstream Wnt activation signal to 
tightly control β-catenin nuclear localization and activity. APC inactivation leads to strong 
activation of the β-catenin pathway and is the most common initiating oncogenic event of 
intestinal dysplasia (35). Although early studies demonstrated induction of PPAR-δ in 
intestinal tumors that were formed upon loss of APC or by chemical mutagenesis, 
subsequent reports in both rodents and humans failed to establish an unequivocal induction 
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of PPAR-δ expression or activity in intestinal cancers (36). Several studies have utilized 
either whole body or intestinal specific genetic ablation of PPAR-δ to delineate the precise 
function of PPAR-δ in tumor prone APCmin/+ mice (mice with nonsense mutation in Apc 
gene that results in a truncated protein) or chemically induced models of intestinal 
tumorigenesis. While some studies found a pro-tumorgenic role for PPAR-δ, others posited 
an anti-tumorigenic function. Conflicting results from these loss of function studies have 
raised important questions regarding the role of PPAR-δ in intestinal tumorigenesis (23, 37–
39). In contrast, however, gain of function studies that utilized the PPAR-δ agonist 
GW501516 more consistently demonstrated that PPAR-δ activation mediates a pro-
tumorigenic phenotype in the intestine (40).
These conflicting findings, regarding PPAR-δ necessity in intestinal tumorigenesis, may be 
due to different genetic strategies used to disrupt PPAR-δ function. Studies that supported an 
anti-tumorigenic role for PPAR-δ in APCmin/+ mice utilize germline disruption of PPAR-δ 
exon 8 (37, 38). Whereas ablation of PPAR-δ by disrupting exon 4 failed to decrease tumor 
incidence in Apcmin/+ mice but led to a reduction in size of the largest intestinal adenomas 
(23). However, deletion of PPAR-δ exon 4 and part of exon 5 significantly diminished tumor 
numbers in Apcmin/+ mice, and exon4 deletion reduced dysplastic lesions in Apcmin/+ mice 
exposed to chemical injury (39, 41). Some of the discrepancy likely arises from the fact that 
disruption of exon 8 (the last PPAR-δ exon) may produce a hypomorphic protein, while 
disruption of exon 4 (an essential portion of the PPAR-δ DNA binding domain) ablates 
PPAR-δ activity (42). Lastly, it is important to point out that these studies used germline 
PPAR-δ mutants. More recently, intestine-specific PPAR-δ loss (targeting exon 4) decreased 
the numbers of dysplastic lesions in response to chemical mutagenesis (42). Another 
possible confounder in these studies is the use of different genetic backgrounds, which is 
known to influence tumor susceptibility in Apcmin/+ mice or to chemical injury (1).
Dietary regulation of stemness and tumor initiation
As discussed above, accumulating evidence underscores the importance of PPAR-δ pathway 
in health and disease. However little is known about how PPAR-δ contributes to the 
regulation of stemness and tumor initiation in response to diet-induced physiologies. Diet is 
a modifiable lifestyle factor that has a profound impact on mammalian physiology, health, 
and disease including cancer. Long-lived mammalian tissue-specific stem cells play a key 
role in how tissues adapt to diverse diet-induced physiological states. Such stem cells 
dynamically remodel tissue composition in response to physiological cues by altering the 
balance between self-renewal and differentiation divisions (43). Factors that increase 
somatic stem cell self-renewal division rate are implicated to elevate cancer risk (44, 45). 
This suggests that dietary interventions that boost stem cell self-renewal increase the 
potential pool of cells that can undergo mutagenesis and give rise to cancer.
Consistent with this notion, we recently demonstrated that a pro-obesity high fat diet (HFD)-
activated PPAR-δ program augments the numbers, proliferation and function of ISCs in the 
mouse intestine, providing a possible explanation to the long-sought link between diet-
induced obesity and cancer (7, 46). In addition, intestinal adaptations to a long-term HFD 
not only enabled ISCs to acquire niche independence (i.e. initiate mini-intestines in culture 
Beyaz and Yilmaz Page 4





















without need of their Paneth niche) but also allowed non-stem cell progenitors to obtain 
stem-cell attributes. These changes effectively augmented the numbers of cells within the 
intestine that possessed stemness and that could initiate tumors upon loss of the APC tumor 
suppressor gene (7). Moreover, enforced PPAR-δ activation mimicked many of these effects 
of a HFD. As mentioned, there are differing opinions on the role of PPAR-δ in intestinal 
tumor initiation. However, these findings demonstrate that PPAR-δ activation in ISCs and 
progenitors has pro-tumorigenic effects in the intestine and raises the possibility that PPAR-
δ inhibition in the setting of a HFD may dampen tumor initiation, progression, or both.
An important question is whether a HFD has similar stem cell enhancing effects in other 
tissues. Interestingly, in contrast to the enhanced stemness observed in the intestine, HFD 
decreases neural progenitor cells proliferation and hippocampal neurogenesis by increasing 
lipid peroxidation and reducing BDNF levels in hippocampus (47). On the other hand, HFD 
alters the differentiation potential of bone marrow-derived mesenchymal stem cells (MSCs), 
subcutaneous adipose-derived stem cells (sqASCs), and infrapatellar fat pad-derived stem 
cells (IFP). Notably, the fatty acid constituents of the diet in part mediated this effect, 
implicating a possible role for PPAR-δ signaling (48). Also, the impact of a HFD in 
hematopoiesis is context dependent. A recent study demonstrated that a maternal HFD 
compromises the expansion of the fetal HSPC pool and hematopoietic lineage specification. 
Conversely, adult hematopoiesis is augmented in response to HFD-induced obesity (49, 50). 
The fact that PPAR-δ-activated fatty acid oxidation drives hematopoietic stem cell self-
renewal (51) suggests that HFD-mediated regulation of hematopoiesis may involve PPAR-δ 
function. Nonetheless, whether a HFD or PPAR-δ is linked to tumor initiation in these 
tissues warrants further investigation.
CLINICAL-TRANSLATIONAL ADVANCES
Despite the fact that preclinical studies have provided evidence that PPAR-δ agonists 
possess therapeutic value in the treatment of several metabolic diseases, there are currently 
no FDA approved agonists for PPAR-δ.(5, 9). This is in contrast to PPAR-α and PPAR-γ, 
which have FDA approved agonists that are standard of care for metabolic disorders such as 
hyperlipidemia and diabetes. Although clinical trials revealed that short-term administration 
of PPAR-δ agonists GW501516 (NCT00841217) (52) and MBX-8025 (NCT00701883) (53) 
had beneficial effects in patients with metabolic syndrome, pre-clinical long-term studies in 
mice indicated that PPAR-δ agonists might have pro-tumorigenic effects, thus dampening 
enthusiasm for these compounds in human trials.
Several studies have suggested that PPAR-δ expression has prognostic value for cancer 
patients including those with colorectal cancer (54, 55). However, there are inconsistencies 
in the reported PPAR-δ expression levels of different human tumors compared to normal 
tissue as well as how PPAR-δ expression correlates with prognosis. For instance, a study 
that examined 52 colorectal cancer patients found that PPAR-δ and COX-2 expression in 
tumors negatively correlates with patient survival (54). However, another study with 141 
colorectal cancer patients revealed that higher expression of PPAR-δ in primary colorectal 
tumors was associated with lower expression of Ki67 (a cellular marker for proliferation), a 
higher frequency of stage I cases, a lower frequency of later stage cases, and a lower rate of 
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lymph node metastasis (55). More studies are required to precisely ascertain the molecular 
mechanisms that PPAR-δ employs during cancer initiation and progression and how this 
impacts patient prognosis.
PPAR-δ polymorphisms have been associated with physical performance (56), diabetes (57), 
obesity (58) and cancer (59, 60). A recent study focusing at colorectal cancer patients 
identified 7 novel variants among 22 inherited or acquired PPARD variants. Interestingly, 4 
recurrent variants were detected in or adjacent to exon 4, which encodes an essential portion 
of the PPAR-δ DNA-binding domain, suggesting that these variants have functional 
significance (60). Although these variants may have clinical importance, the effect of PPAR-
δ polymorphisms on gene expression or function of PPAR-δ is still poorly understood.
Our recent data indicates that HFD-activated PPAR-δ engages a specific β-catenin program 
that involves expression of genes implicated in intestinal tumorigenesis such as Jag1 and 
Bmp4 in ISCs and progenitors (7). Future studies need to address whether increased 
expression of Jag1 or Bmp4 has any prognostic or correlative value in colorectal cancer that 
arise in obese patients. Furthermore, it will be important to determine the functions of 
PPAR-δ in the setting of diverse tissues, cell-types, diets, and risk factors that are associated 
with cancer in humans. The fact that PPAR-δ links dietary regulation of stemness to tumor 
initiation in the intestine raises the possibility of a new therapeutic approach in the treatment 
of intestinal cancers in obesity (7) such as exploiting possible PPAR-δ dependencies in 
tumors that arise in a HFD or obesity. Uncovering the cellular and molecular mechanisms by 
which PPAR-δ drives its effects may lead to new therapeutic insights, especially in those 
cancers with high PPAR-δ activity.
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Mechanisms of PPAR-δ mediated gene regulation. Dietary fatty acids, synthetic small 
molecule agonists (GW501516), intracellular fatty acids and metabolites may activate 
PPAR-δ pathway. Two major models have been proposed regarding delivery of PPAR-δ 
ligands. First, fatty acid binding proteins (FABPs) can transport fatty acids to the nucleus. 
Second, ligands are produced in the nucleus as a result of nuclear lipid metabolism. Ligand 
binding activates PPAR-δ and leads to regulation of several important biological processes. 
First, PPAR-δ partners with retinoid X receptor (RXR) and binds to peroxisome proliferator 
response elements (PPRE) to activate the expression of genes involved in lipid metabolism 
(1). In addition, PPAR-δ interacts with β-catenin, which is a key transcription factor for cell 
fate determination and assists β-catenin to induce gene expression in order to modulate 
stemness in response to dietary cues like fatty acids (2). Lastly, PPAR-δ inhibits 
inflammatory gene expression by interfering with NFκB pathway (3).
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